Surgical suture

United States Cardiovascular Needle Market Insights and Forecast Report, 2022-2023 & 2026 - AI is Making Inroads in Cardiovascular Medicine, Improving Prognosis and Treatment Outcomes - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023

The US cardiovascular needle market is foreseen to reach US$36.71 million in 2023, growing at a CAGR of 7.55% during the forecasted period.

Key Points: 
  • The US cardiovascular needle market is foreseen to reach US$36.71 million in 2023, growing at a CAGR of 7.55% during the forecasted period.
  • The treatment of these disorders often requires specialized surgeries, during which cardiovascular needles are used to suture the wounds.
  • Consequently, the increasing prevalence of cardiovascular diseases has driven the demand for cardiovascular devices for diagnosis and treatment, contributing to the growth of the cardiovascular needle market in recent years.
  • Artificial intelligence (AI) is making inroads in cardiovascular medicine, improving prognosis and treatment outcomes.

Global Surgical Equipment Market to Reach $19.3 Billion by 2027

Retrieved on: 
Thursday, November 3, 2022

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Surgical Equipment estimated at US$9.4 Billion in the year 2020, is projected to reach a revised size of US$19.3 Billion by 2027, growing at a CAGR of 10.7% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $2.6 Billion, While China is Forecast to Grow at 15.9% CAGR
    The Surgical Equipment market in the U.S. is estimated at US$2.6 Billion in the year 2020.
  • China, the world`s second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2027 trailing a CAGR of 15.8% over the analysis period 2020 to 2027.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.7 Billion by the year 2027.

Anchora Medical Receives FDA clearance for its Su2ura® Minimally-Invasive Surgical Suturing Device

Retrieved on: 
Thursday, July 1, 2021

CAESAREA, Israel, July 1, 2021 /PRNewswire-PRWeb/ -- Anchora Medical , an Israel-based medical device company, announced today that it has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) to market its Su2ura Approximation Device, an innovative, automated suturing device used in laparoscopic surgery, for the placement of interrupted or running stitches in soft tissue.

Key Points: 
  • CAESAREA, Israel, July 1, 2021 /PRNewswire-PRWeb/ -- Anchora Medical , an Israel-based medical device company, announced today that it has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) to market its Su2ura Approximation Device, an innovative, automated suturing device used in laparoscopic surgery, for the placement of interrupted or running stitches in soft tissue.
  • The Su2ura Approximation Device enables a simple, automated single-trigger operation that combines simplicity, strength, and durability of sutures during MIS.
  • By simplifying the suturing procedure, the Su2ura Approximation Device aims to shorten operation time, lower costs, reduce risks and improve clinical outcomes.
  • The proprietary, patent protected Su2ura Approximation Device incorporates tiny stainless-steel smart anchors threaded on a surgical thread to create sutures seamlessly adjusted by the surgeon for precision suturing in small spaces.

Ethicon Plus Sutures Become First and Only Sutures With Antibacterial Protection Recommended for Use in NHS by NICE Medical Technologies Guidance

Retrieved on: 
Tuesday, June 29, 2021

By lowering the risk of SSIs1, Plus Sutures may be able to help the NHS at a time of unprecedented pressure.

Key Points: 
  • By lowering the risk of SSIs1, Plus Sutures may be able to help the NHS at a time of unprecedented pressure.
  • * Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates.
  • Storch ML, Rothenburger SJ, Jacinto G. Experimental efficacy study of Coated VICRYL Plus Antibacterial Sutures in guinea pigs challenged with Staphylococcus aureus.
  • Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of Monocryl Plus Antibacterial Suture (polgelcaprone 25 with triclosan).

Quick Tube Medical Announces "NEEDLE D" Product Launch

Retrieved on: 
Thursday, May 20, 2021

b'FLETCHER, N.C., May 20, 2021 /PRNewswire-PRWeb/ --Leaders from Quick Tube Medical have just announced that the Company has begun the manufacturing process for a decompression needle kit for use with acute pneumothorax or traumatic arrest.

Key Points: 
  • b'FLETCHER, N.C., May 20, 2021 /PRNewswire-PRWeb/ --Leaders from Quick Tube Medical have just announced that the Company has begun the manufacturing process for a decompression needle kit for use with acute pneumothorax or traumatic arrest.
  • The new product, known as "Needle D," is incision-less, suture-less and includes a locking stabilizer.
  • For more information, visit Quick Tube Medical .
  • Find Quick Tube Medical on LinkedIn .\n'

Global Surgical Wound Closure Devices Market Outlook and Forecast Report 2021-2026: Market to Grow at a CAGR of 6% - Shifting End-Users Preference Toward Non-Invasive Wound Closure Devices

Retrieved on: 
Wednesday, April 28, 2021

b'DUBLIN, April 28, 2021 /PRNewswire/ -- The "Surgical Wound Closure Devices Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global surgical wound closure devices market by revenue is expected to grow at a CAGR of approx.

Key Points: 
  • b'DUBLIN, April 28, 2021 /PRNewswire/ -- The "Surgical Wound Closure Devices Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global surgical wound closure devices market by revenue is expected to grow at a CAGR of approx.
  • 6% during the period 2021-2026.\nThe wound closure devices market has been adversely affected since the breakout of the COVID-19 pandemic.
  • In 2020, surgical sutures and needles accounted for over 41% of the global surgical wound closure devices market share.
  • What is the market size of the surgical wound closure devices market during the period 2020-2026?\n2.

Vivasure Medical Begins Clinical Evaluation of Next-Generation PerQseal+ Device

Retrieved on: 
Tuesday, April 20, 2021

The study will evaluate the company\xe2\x80\x99s next-generation PerQseal+ device with an enhanced bioabsorbable patch designed to address more complex patient anatomies.\nThe company\xe2\x80\x99s PerQseal device is the first sutureless, fully absorbable synthetic implant for large-bore vessel punctures.

Key Points: 
  • The study will evaluate the company\xe2\x80\x99s next-generation PerQseal+ device with an enhanced bioabsorbable patch designed to address more complex patient anatomies.\nThe company\xe2\x80\x99s PerQseal device is the first sutureless, fully absorbable synthetic implant for large-bore vessel punctures.
  • Vascular complications remain a significant challenge for TAVR, and these complications are associated with more adverse events and increased costs.
  • Vivasure operates a fully integrated R&D and ISO 13485 certified manufacturing facility and is backed by leading international medtech investors.
  • For more information, please visit www.vivasuremedical.com .\nThe PerQseal\xc2\xae is not available for sale in the United States.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005331/en/\n'

Surgical Suture Market worth $4.9 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, April 1, 2021

Based on product, the surgical sutures market has been segmented into suture threads and automated suturing devices.

Key Points: 
  • Based on product, the surgical sutures market has been segmented into suture threads and automated suturing devices.
  • In 2020, the suture threads segment accounted for the largest market share of 82.6%.
  • In 2020, the multifilament sutures segment accounted for the largest share of 67.5% of the surgical suture threads market.
  • Based on end users, the surgical sutures market is segmented into hospitals, ambulatory surgical centers, and clinics and physicians' offices.

Surgical Suture Market worth $4.9 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, April 1, 2021

Based on product, the surgical sutures market has been segmented into suture threads and automated suturing devices.

Key Points: 
  • Based on product, the surgical sutures market has been segmented into suture threads and automated suturing devices.
  • In 2020, the suture threads segment accounted for the largest market share of 82.6%.
  • In 2020, the multifilament sutures segment accounted for the largest share of 67.5% of the surgical suture threads market.
  • Based on end users, the surgical sutures market is segmented into hospitals, ambulatory surgical centers, and clinics and physicians' offices.

In2Bones Continues Driving Innovation with Launch of the Hercules™ Suture Anchors and AlloAid® Wedges

Retrieved on: 
Tuesday, February 23, 2021

In2Bones Global, Inc. today announces the U.S. launch of its Hercules Suture Anchor System and AlloAid Wedges for lower extremity surgeries.

Key Points: 
  • In2Bones Global, Inc. today announces the U.S. launch of its Hercules Suture Anchor System and AlloAid Wedges for lower extremity surgeries.
  • View the full release here: https://www.businesswire.com/news/home/20210223005221/en/
    In2Bones Global, Inc. today announces the U.S. launch of its Hercules Suture Anchor System and AlloAid Wedges for lower extremity surgeries.
  • (Graphic: Business Wire)
    With the Hercules Suture Anchor System, In2Bones sees an opportunity for sales acceleration with soft tissue fixation for the multi-billion sports medicine market.
  • The Hercules Suture Anchor and AlloAid Wedge Systems provide pull-through sales opportunities in previously unaddressed areas of the In2Bones portfolio of products.